Robert H. Jones

29.6k citations

233 papers · 13.8k indexed · 3 hit papers · h-index 61

Impact in

Cardiology and Cardiovascular Medicine top 0.1%
- Cardiac Valve Diseases and Treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiovascular Function and Risk Factors
- Acute Myocardial Infarction Research
Critical Care and Intensive Care Medicine top 0.2%

Papers in

Cardiology and Cardiovascular Medicine 112
- Cardiovascular Function and Risk Factors 37
- Cardiac Valve Diseases and Treatments 35
- Cardiac, Anesthesia and Surgical Outcomes 23
Radiology, Nuclear Medicine and Imaging 74
- Cardiac Imaging and Diagnostics 56

Co-authors: Daniel B. Mark Mark F. Newman Edward L. Hannan David C. Sabiston J. G. Rêves Hilary P. Grocott Peter K. Smith Yi‐Ju Li
Journals: Circulation (27 papers)Journal of the American College of Cardiology (21 papers)Journal of Clinical Oncology (18 papers)Journal of Thoracic and Cardiovascular Surgery (17 papers)The American Journal of Cardiology (16 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Robert H. Jones

232 papers receiving 13.0k citations

Hit Papers

align trajectories log scale

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial 2018 · 281 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2016 New England Journal of Medicine
2001 New England Journal of Medicine

Peers

Countries citing papers authored by Robert H. Jones

Since Specialization

Citations

This map shows the geographic impact of Robert H. Jones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Jones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Jones more than expected).

Fields of papers citing papers by Robert H. Jones

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Jones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Jones. The network helps show where Robert H. Jones may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert H. Jones, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert H. Jones Line = papers co-authored together Robert H. Jones links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer British Journal of Cancer ·Valentine M. Macaulay, Simon Lord, Syed A. Hussain, Pablo Maroto, Robert H. Jones, Miguel Ángel Climent, Natalie Cook, Chia‐Chi Lin, Shian‐Shiang Wang, Diletta Bianchini, Mark Bailey, M. Wang, Thomas Bogenrieder, Johann S. de Bono	2023	3
2	Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer NEJM Evidence ·Karim Fizazi, Alice Bernard‐Tessier, Guilhem Roubaud, Tapio Utriainen, Philippe Barthélémy, Aude Fléchon, Geon-Rae Kim, Gwénaëlle Gravis, Raffaele Ratta, Robert H. Jones, Omi Parikh, Minna Tanner, Emmanuel S. Antonarakis, Capucine Baldini, A. Бoлтaкc, Chris Garratt, Tarja Ikonen, Pasi Pohjanjousi, Heikki Joensuu, Natalie Cook	2023	13
3	A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer British Journal of Cancer ·Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji	2023	22
4	A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer Clinical Cancer Research ·Robert H. Jones, Ruth Plummer, Víctor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Hendrik‐Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah P. Blagden, Alan Anthoney, Barbara Klencke, Mark Kowalski, Udai Banerji	2022	27
5	Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial The Lancet Oncology ·Sacha J. Howell, Angela Casbard, Margherita Carucci, Kate Ingarfield, Rachel Butler, Siân Morgan, Ajit Dhake, C. Bale, Pavel Bezecny, 袁春生, Chris Twelves, Ramachandran Venkitaraman, Simon Waters, Elza C. de Bruin, Gaia Schiavon, Andrew Foxley, Robert H. Jones	2022	87
6	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer European Urology Focus ·Katriina Peltola, Petri Bono, Robert H. Jones, Egils Vjaters, Pirjo Nykänen, Annamari Vuorela, Riikka Oksala, Pasi Pohjanjousi, Mika Mustonen, Karim Fizazi, Christophe Massard	2018	5
7	Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer Clinical Cancer Research ·Martin Scurr, Tom Pembroke, Anja Bloom, David C. S. Roberts, Amanda Thomson, Kathryn Smart, Hayley Bridgeman, Richard Adams, A. Brewster, Robert H. Jones, Sarah Gwynne, Daniel G. Blount, Richard Harrop, Robert K. Hills, Awen Gallimore, Andrew Godkin	2017	119
8	Impact of Surgical Ventricular Reconstruction on Sphericity Index in Patients with Ischaemic Cardiomyopathy: Follow-Up from the STICH Trial European Journal of Heart Failure ·Jin‐Oh Choi, Richard C. Daly, Grace Lin, Brian D. Lahr, Heather J. Wiste, Thomas M. Beaver, Attilio Iacovoni, Marcin Malinowski, Ivar Friedrich, Jean L. Rouleau, Roberto Favaloro, George Sopko, Iréne Lang, Harvey D. White, Carmelo A. Milano, Robert H. Jones, Kerry L. Lee, Eric J. Velazquez, Jae K. Oh	2015	19
9	Inducible Myocardial Ischemia and Outcomes in Patients With Coronary Artery Disease and Left Ventricular Dysfunction Journal of the American College of Cardiology ·Julio A. Panza, Thomas A. Holly, Federico M. Asch, Lilin She, Patricia A. Pellikka, Eric J. Velazquez, Kerry L. Lee, Salvador Borges‐Neto, Pedro Sílvio Farsky, Robert H. Jones, Daniel S. Berman, Robert O. Bonow	2013	114
10	Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial Circulation ·Marek Deja, Paul Grayburn, Benjamin Sun, Vivek Rao, Lilin She, Michał Krejca, Anil Jain, Yeow Leng Chua, Richard C. Daly, Michele Senni, Krzysztof Mokrzycki, Lorenzo Menicanti, Jae K. Oh, Robert E. Michler, Krzysztof Wróbel, André Lamy, Eric J. Velazquez, Kerry L. Lee, Robert H. Jones	2012	141
11	The Year in Cardiovascular Surgery Journal of the American College of Cardiology ·Robert H. Jones	2008	9
12	The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial Journal of Thoracic and Cardiovascular Surgery ·Eric J. Velazquez, Kerry L. Lee, Christopher M. O’Connor, Jae K. Oh, Robert O. Bonow, Gerald M. Pohost, Arthur M. Feldman, Daniel B. Mark, Julio A. Panza, George Sopko, Jean L. Rouleau, Robert H. Jones	2007	131
13	A comparison of short- and long-term outcomes after off-pump and on-pump coronary artery bypass graft surgery with sternotomy Journal of the American College of Cardiology ·Michael Racz, Edward L. Hannan, O. Wayne Isom, Valavanur A. Subramanian, Robert H. Jones, Jeffrey P. Gold, Thomas J. Ryan, Alan Hartman, Alfred T. Culliford, Edward V. Bennett, Robert Lancey, Eric A. Rose	2004	97
14	Usefulness of Serial Radionuclide Angiography in Predicting Cardiac Death After Coronary Artery Bypass Grafting and Comparison With Clinical and Cardiac Catheterization Data The American Journal of Cardiology ·Salvador Borges‐Neto, Leslee J. Shaw, Karen Kesler, Junchi Li, Eric D. Peterson, R. Edward Coleman, Robert H. Jones	1997	21
15	Prognosis in patients with coronary artery disease by equilibrium radionuclide measurements of left ventricular function during exercise Journal of the American College of Cardiology ·Karen Kesler, Leslee J. Shaw, Sheila K. Heinle, Salvador Borges‐Neto, Robert E. Coleman, Robert H. Jones	1996	3
16	Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery Journal of the American College of Cardiology ·Robert H. Jones, Edward L. Hannan, K.E. Hammermeister, Elizabeth R. DeLong, Gerald T O’Connor, Russell V. Luepker, Victor Parsonnet, David B. Pryor	1996	237
17	Early and late changes in left ventricular systolic performance after percutaneous aortic balloon valvuloplasty The American Journal of Cardiology ·David H. Harpole, Charles J. Davidson, Thomas N. Skelton, Katherine B. Kisslo, Robert H. Jones, Donya Ahmadi	1990	7
18	High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma Cancer ·Nick Thatcher, Michael Lind, G.R. Morgenstern, Walter Jackson Williams, Julie Mehta, Robert H. Jones, Peter Craig	1989	21
19	Relation of coronary artery stenosis and pressure gradient to exercise-induced ischemia before and after coronary angioplasty Journal of the American College of Cardiology ·Richard J. Peterson, Spencer B. King, WILLIAM A. FAJMAN, John S. Douglas, A Grüntzig, John Aliferis, Robert H. Jones	1987	18
20	Noninvasive determination of exercise cardiac function following Fontan operation Journal of Thoracic and Cardiovascular Surgery ·Richard J. Peterson, Robert H. Franch, WILLIAM A. FAJMAN, Marcelo Araújo Frazão, Robert H. Jones	1984	29

About Robert H. Jones

Robert H. Jones is a scholar working on Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging, Complementary and alternative medicine, Pulmonary and Respiratory Medicine and Surgery, having authored 233 papers that have together received 13.8k indexed citations. Recurring topics across this work include Cardiac Imaging and Diagnostics (56 papers), Cardiovascular Function and Risk Factors (37 papers), Cardiac Valve Diseases and Treatments (35 papers), Cardiac, Anesthesia and Surgical Outcomes (23 papers), Prostate Cancer Treatment and Research (22 papers), Cardiac Structural Anomalies and Repair (17 papers), Coronary Interventions and Diagnostics (17 papers) and Cardiac and Coronary Surgery Techniques (15 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (8.7k citations), Critical Care and Intensive Care Medicine (974 citations), Radiology, Nuclear Medicine and Imaging (3.7k citations), Developmental Neuroscience (566 citations) and Surgery (5.5k citations). Robert H. Jones has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Daniel B. Mark, Mark F. Newman, Edward L. Hannan, David C. Sabiston, J. G. Rêves, Hilary P. Grocott, Peter K. Smith, Yi‐Ju Li, Jerry Kirchner and James A. Blumenthal. Their work appears in journals such as Circulation, Journal of the American College of Cardiology, Journal of Clinical Oncology, Journal of Thoracic and Cardiovascular Surgery and The American Journal of Cardiology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact